[en] BACKGROUND: Crohn's disease (CD)-associated dysbiosis could predispose patients to relapse. Gut microbiota composition of patients from the prospective cohort study designed to identify predictive factors of clinical relapse after infliximab discontinuation (STORI Study) was investigated to determine the impact of dysbiosis in CD relapse. METHODS: Fecal samples from 33 patients with CD in this cohort were collected at baseline, 2 months, 6 months, and at the end of the follow-up period (19 relapsers and 14 nonrelapsers). Healthy volunteers subjects (n = 29) were used as a control group. The fecal microbiota composition was assessed using quantitative PCR, and comparisons between the patient groups were made at different time points using the Wilcoxon test. The analysis of the time-to-relapse was performed according to the baseline median level of each bacterial signal. RESULTS: Dysbiosis was observed in patients with CD compared with healthy subjects, and it was characterized by low mean counts of Firmicutes (Clostridium coccoides [P = 0.0003], C. leptum [P < 0.0001], and Faecalibacterium prausnitzii [P = 0.003]). Lower rates of Firmicutes were seen in relapsers compared with nonrelapsers. Moreover, a low rate of F. prausnitzii (P = 0.014) and a low rate of Bacteroides (P = 0.030) predicted relapse independently from high C reactive protein level (P = 0.0001). CONCLUSIONS: In this work, we report that CD-associated dysbiosis, characterized by a decrease in Firmicutes, correlates with the time-to-relapse after infliximab withdrawal. A deficit in some bacterial groups or species, such as F. prausnitzii, may represent a predictive factor for relapse. Restoring normobiosis in CD could be a new goal for optimal CD management.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Rajca, Sylvie
Grondin, Virginie
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Hugot JP, Chamaillard M, Zouali H., et al Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411: 599-603. (Pubitemid 32531408)
Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroen-terology. 2004; 126: 1620-1633. (Pubitemid 38649878)
MacDermott RP. Alterations of the mucosal immune system in inflammatory bowel disease. J Gastroenterol. 1996; 31: 907-916. (Pubitemid 27042277)
Allez M, Mayer L. Regulatory T cells: peace keepers in the gut. Inflamm Bowel Dis. 2004; 10: 666-676. (Pubitemid 39276480)
Khor B, Gardet A, Xavier RJ Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011; 474: 307-317.
Sokol H, Seksik P, Rigottier-Gois L, et al Specificities of the fecal micro-biota in inflammatory bowel disease. Inflamm Bowel Dis. 2006; 12: 106-111.
Sokol H, Seksik P, Furet J.P., et al Low counts of Faecalibacterium praus-nitzii in colitis microbiota. Inflamm Bowel Dis. 2009; 15: 1183-1189.
Darfeuille-Michaud A., Boudeau J, Bulois P., et al High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology. 2004; 127: 412-421. (Pubitemid 39091889)
Sokol H, Pigneur B, Watterlot L., et al Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008; 105: 16731-16736.
Cosnes J, Gower-Rousseau C, Seksik P., et al Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011; 140: 1785-1794.
Beaugerie L, Seksik P, Nion-Larmurier I, et al Predictors of Crohn's disease. Gastroenterology. 2006; 130: 650-656. (Pubitemid 43374514)
Costa F, Mumolo MG, Ceccarelli L, et al Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005; 54: 364-368. (Pubitemid 40299092)
Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011; 140: 1817-1826 e2.
Ljung T, Karlen P, Schmidt D., et al Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut. 2004; 53: 849-853. (Pubitemid 38662135)
Kiss LS, Szamosi T, Molnar T., et al Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Aliment Pharmacol Ther. 2011; 34: 911-922.
Louis E, Mary JY, Vernier-Massouille G, et al Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after in-fliximab therapy is stopped. Gastroenterology. 2012; 142: 63-70 e5.
Mariat D, Firmesse O, Levenez F., et al The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol. 2009; 9: 123.
Suzuki MT, Taylor LT, DeLong EF Quantitative analysis of small-subunit rRNA genes in mixed microbial populations via 50-nuclease assays. Appl Environ Microbiol. 2000; 66: 4605-4614.
Furet JP, Firmesse O, Gourmelon M., et al Comparative assessment of human and farm animal faecal microbiota using real-time quantitative PCR. FEMS Microbiol Ecol. 2009; 68: 351-362.
Lyons SR, Griffen AL, Leys EJ Quantitative real-time PCR for Porphyr-omonas gingivalis and total bacteria. J Clin Microbiol. 2000; 38: 2362-2365. (Pubitemid 30414365)
Huijsdens XW, Linskens RK, Mak M, et al Quantification of bacteria adherent to gastrointestinal mucosa by real-time PCR. J Clin Microbiol. 2002; 40: 4423-4427. (Pubitemid 35434925)
Matsuda K, Tsuji H, Asahara T., et al Sensitive quantitative detection of commensal bacteria by rRNA-targeted reverse transcription-PCR. Appl Environ Microbiol. 2007; 73: 32-39. (Pubitemid 46079932)
Sobhani I, Tap J, Roudot-Thoraval F, et al Microbial dysbiosis in colo-rectal cancer (CRC) patients. PLoS One. 2011; 6:e16393.
Sokol H, Lay C, Seksik P., et al Analysis of bacterial bowel communities of IBD patients: what has it revealed? Inflamm Bowel Dis. 2008; 14: 858-867. (Pubitemid 351898071)
Manichanh C, Rigottier-Gois L, Bonnaud E., et al Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 2006; 55: 205-211. (Pubitemid 43117279)
Chow J, Tang H, Mazmanian SK Pathobionts of the gastrointestinal micro-biota and inflammatory disease. Curr Opin Immunol. 2011; 23: 473-480.
Kelly D, Mulder IE Microbiome and immunological interactions. Nutr Rev. 2012; 70(SUPPL. 1):S18-S30.
Atarashi K, Tanoue T, Shima T., et al Induction of colonic regulatory T cells by indigenous Clostridium species. Science. 2011; 331: 337-341.
Gaboriau-Routhiau V., Rakotobe S, Lecuyer E., et al The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity. 2009; 31: 677-689.
Ivanov II, Atarashi K, Manel N., et al Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009; 139: 485-498.
Gersemann M, Wehkamp J, Stange EF Innate immune dysfunction in inflammatory bowel disease. J Intern Med. 2012; 271: 421-428.
Frantz AL, Rogier EW, Weber C.R., et al Targeted deletion of MyD88 in intestinal epithelial cells results in compromised antibacterial immunity associated with downregulation of polymeric immunoglobulin receptor, mucin-2, and antibacterial peptides. Mucosal Immunol. 2012; 5: 501-512.
Ridlon JM, Kang DJ, Hylemon PB Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2006; 47: 241-259. (Pubitemid 43276911)
Batta AK, Salen G, Arora R., et al Side chain conjugation prevents bacterial 7-dehydroxylation of bile acids. J Biol Chem. 1990; 265: 10925-10928.
Duboc H, Rajca S, Rainteau D., et al Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2012; 62: 531-539.
Varyukhina S, Freitas M, Bardin S., et al Glycan-modifying bacteria-derived soluble factors from Bacteroides thetaiotaomicron and Lactoba-cillus casei inhibit rotavirus infection in human intestinal cells. Microbes Infect. 2012; 14: 273-278.
Fu J, Wei B, Wen T., et al Loss of intestinal core 1-derived O-glycans causes spontaneous colitis in mice. J Clin Invest. 2011; 121: 1657-1666.
Jacobi CA, Grundler S, Hsieh C.J., et al Quorum sensing in the probiotic bacterium Escherichia coli Nissle 1917 (Mutaflor)-evidence that furano-syl borate diester (AI-2) is influencing the cytokine expression in the DSS colitis mouse model. Gut Pathog. 2012; 4: 8.
